Granulomatous amoebic encephalitis caused by Balamuthia mandrillaris is an uncommon infection for which there is no optimal therapy. We describe a young, female patient who presented with extensive cutaneous and neurological involvement and who recovered after receiving prolonged treatment with miltefosine, fluconazole, and albendazole.
a young patient with Balamuthia encephalitis with a combination regimen of miltefosine, fluconazole, and albendazole.
Case report. A 21-year-old woman presented in August 2006 with a long-term history of cutaneous lesions on her right knee. Four years before admission, she had noticed several papular, erythematous, and painless lesions that had appeared 2 weeks after a fall in front of her house. The lesions coalesced to form a violaceus and indurate plaque covering the entire right knee. Empirical therapy was started at another institution with topical antifungal creams that contained fluconazole and clotrimazole plus topical steroids, which were administered for almost 1 year, followed by a combination of oral fluconazole (150 mg per day for ∼45 days) and subsequent addition of clarithromycin (1500 mg per day) and trimethoprim-sulfamethoxazole (TMP-SMX; 320 mg/1600 mg per day) for 8 months, without improvement.
The patient was born in Lima, Peru, and has resided there for her entire life. She denied travel or specific occupational exposure, including gardening and swimming in brackish, fresh, or sea water. She noticed enlargement of the lesion on the right knee and the appearance of 3 new papular lesions-2 of them around the plaque on the right knee, and the third on the left thigh-in February 2006. Both lesions subsequently evolved into violaceus plaques. She was first seen at our institution 4 months later, where a skin biopsy of the lesion on the right knee was performed ( Figure 1A ). Histopathologic examination revealed a dense inflammatory infiltrate of the dermis composed of lymphocytes, plasma cells, and ill-defined granulomas, with great number of multinucleated giant cells located inside and outside the granulomas. A microorganism with a nucleus that has a large, central karyosome and a vacuolated cytoplasm, compatible with an amoebic trophozoite, was observed ( Figure  1B ). In addition, B. mandrillaris was isolated from a skin sample cultivated in an axenic culture prepared with monkey kidney cells [7] . Polymerase chain reaction of a skin sample also yielded positive results for B. mandrillaris (the amplification was performed using the primer mitochondrial 16S rRNA gene from B. mandrillaris as a target) [9] . A skin biopsy sample was sent to the Public Health Department of California (Sacramento) and to the Centers for Disease Control and Prevention (Atlanta, GA), where B. mandrillaris infection was confirmed by immunohistochemical staining in September 2006. A brain computed tomograph, without contrast enhancement, yielded normal findings at this time. Empirical therapy was started with itraconazole (200 mg per day), and albendazole (400 mg per day). The enlargement of the lesions continued despite medical treatment, and the patient was hospitalized in October 2006 to receive amphotericin B (cumulative dose, 1.5 g), in addition to itraconazole and albendazole. The lesions improved initially, but reactivation of the lesion on the left thigh and the appearance of 2 new small papular lesions (one on the left breast and the other one on her back) were observed in February 2007. Biopsy of the lesion on the back was performed; the biopsy findings were the same as described above. A surgical resection of the new lesions was performed, and TMP-SMX (320 mg/1600 mg by day) was added to the treatment regimen, without improvement.
The patient was readmitted to the hospital in May 2007 because of reactivation of the lesion on the surgical wound on Figure 1C and 1D) . Treatment with amphotericin B, TMP-SMX, clarithromycin, and artesunate was discontinued; itraconazole was changed to fluconazole to optimize the penetration of the azole into the CNS; albendazole treatment was continued, and oral miltefosine (150 mg per day for 12 days and 100 mg per day thereafter) was added in mid-June 2007. The cutaneous lesions on the knee abruptly changed, developing a scaly, crusty surface ( Figure 1E 1 week after the patient started this regimen. The headache disappeared by the second week of this regimen, and fever waned by the fourth week. The skin lesion improved, becoming less scaly and flat, until it eventually disappeared. The patient did well, with regression of all neurological symptoms. She was discharged home with the prescribed antibiotics in August 2007. Significant improvement on the size of the neurological lesions was documented after 5 months of treatment ( Figure 1F ). The patient continued to take miltefosine, albendazole, and fluconazole for 7 months. The intracerebral lesions disappeared, as documented by magnetic resonance imaging performed in May 2008 ( Figure 1G ). She remains asymptomatic, all cutaneous lesions have healed ( Figure 1H ), and no recurrence has been recognized as of May 2010.
Discussion. Since the first report of a Balamuthia mandrillaris amoebic infection affecting a baboon in the San Diego Wild Animal Park in 1986 [1] , 1100 human cases have been reported worldwide, with only 6 survivors [4] [5] [6] [7] [8] . In 2003, Deetz et al [5] described 2 patients with extensive CNS involvement who responded to a prolonged treatment regimen (up to 5 years) that included fluocytosine, pentamidine isethionate, fluconazole, sulfadiazine, and a macrolide. A third patient with CNS involvement who responded to a regimen similar to the one described above, but without fluocytosine, was described by Jung et al [6] . A fourth patient from the California Encephalitis Project (CEP) was reported alive and in good health condition three months after diagnosis, details about his treatment were not provided however [8] . Two additional Peruvian patients survived this infection: one patient with CNS involvement survived long-term therapy (6 months) with albendazole and itraconazole, and another patient, who demonstrated cutaneous involvement alone, was treated with surgical resection plus a combination of itraconazole, albendazole and amphotericin B (cumulative dose, 2 g) [3, 4] . A description of the 7 patients who survived Balamuthia infection of the CNS, including the patient in our study, is presented in Table 1 .
Very few drugs have shown in vitro amebicidal activity against B. mandrillaris, including miltefosine [10] , propamidine, and gramicidin S [7] . The amebicidal activity was demonstrated by drug efficacy test using axenic cultures inoculated in tissue culture flasks with growing concentrations of antimicrobials. Most of the available drugs are amebistatic: phenothiazine compounds, pentamidine isethionate, macrolides, azoles, TMP-SMX, and amphotericin B [7] . In addition, B. mandrillaris escapes the effect of antimicrobials by encysting in tissues, establishing chronic infections that may reactivate later [11] . Use of amebicidal drugs for treating this condition may not only kill trophozoites in active lesions, but may also prevent the further dissemination of the infection to the CNS and other organs, which has been invariably observed when amebistatic drugs are used.
Miltefosine is an alkylphosphocholine compound originally developed as an anticancer drug, which is now established as an effective anti-leishmanial therapy. It acts on key enzymes involved in phospholipid and sterol biosynthesis, suggesting that the cell membrane is its main target [12] . In vitro, it stimulates T cells and macrophages to secrete activating cytokines, including interferon-g, and induces production of microbicidal reactive nitrogen and oxygen intermediates, causing cell death by an apoptosis-like effect [13] . A recent report showed good in vitro activity of miltefosine against Balamuthia, Acanthamoeba, and Naegleria species [10] . Miltefosine achieves a high concentration of the active drug in the brain tissue as a result of excellent passage through the brain-blood barrier. In addition, miltefosine carries an acceptable safety profile [10] . This is a potentially critical property of any drug to be successful in treating CNS involvement by free-living amebas.
Although the prognosis of amebic encephalitis caused by B. mandrillaris is still ominous, it may not be invariably fatal. This report on the successful use of a combination regimen that includes 1 amebicidal drug (miltefosine) along with 2 amebistatic drugs capable of crossing the brain-blood barrier (fluconazole and albendazole) provides hope for attaining clinical cure for an otherwise lethal condition. More clinical experience is needed before miltefosine can be recommended as the definitive first-line treatment for amebic encephalitis.
